Ultragenyx Pharmaceutical Inc. RARE

About Ultragenyx Pharmaceutical Inc. (RARE): stock profile, AI score and financials

Ultragenyx Pharmaceutical Inc. (RARE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RARE at 33.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,357 of 2,925 stocks — the bottom half of the AI-ranked universe. RARE scores in the top quartile across institutional flow (86.6), revenue growth (82.5). Areas of concern include balance sheet strength (4.2) and free cash flow (7.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Ultragenyx Pharmaceutical Inc. reports quarterly revenue of $214.0M, net income of $-92.0M, an operating margin of -35.0%. Top institutional holders of RARE by reported 13-F value include BlackRock, RTW INVESTMENTS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. RARE trades on the Nasdaq exchange and files with the SEC under CIK 1515673. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RARE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ultragenyx Pharmaceutical Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1515673 →